Drug Type Small molecule drug |
Synonyms Cefbuperazone, Cefbuperazone sodium (JP17), BMY-25182 + [3] |
Target |
Mechanism PBPs inhibitors(Bacterial penicillin-binding protein inhibitors), Cell wall inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization- |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date- |
Regulation- |
Molecular FormulaC22H29N9NaO9S2 |
InChIKeyHKFFDVOEBVRKTD-FDVIUCIPSA-N |
CAS Registry76648-01-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01736 | Cefbuperazone Sodium |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Bacterial Infections | - | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Respiratory Tract Infections | Phase 3 | CN | 04 Feb 2015 | |
Urinary Tract Infections | Phase 3 | CN | 04 Feb 2015 | |
Hepatobiliary infection | Phase 1 | CN | 27 Aug 2015 | |
Inflammation | Phase 1 | CN | 27 Aug 2015 | |
Connective tissue inflammation | Phase 1 | CN | 29 May 2015 | |
Intrauterine infection | Phase 1 | CN | 29 May 2015 | |
Cholangitis | Phase 1 | CN | 02 Apr 2014 | |
Cholecystitis | Phase 1 | CN | 02 Apr 2014 | |
Cystitis | Phase 1 | CN | 02 Apr 2014 | |
Empyema | Phase 1 | CN | 02 Apr 2014 |